ALTA PROPORCIÓN DE TRANSCRITOS BCR/ABL EN PACIENTES CON LEUCEMIA MIELOIDE CRÓNICA EN COLOMBIA
Palabras clave:
Leucemia, transcritos de fusión, transcritos b2a2 y b3a2, reacción en cadena de la polimerasa (PCR), fusión BCR/ABL, Leukemia, fusion transcripts, b2a2 and b3a2 transcripts, polymerase chain reaction (PCR), BCR/ABL fusionResumen
RESUMENMétodos: Mediante análisis por RT-PCR del RNAm extraído de leucocitos de sangre periférica obtenida de pacientes
Resultados: De doce pacientes evaluados, el 67% (ocho) presentaron el transcrito b2a2 y 33% (cuatro) presentaron el transcrito b3a2.
Conclusión: Esta proporción mayor para b2a2 difiere de lo observado en otros estudios mundiales: Inglaterra, Japón, Italia, España pero se aproxima a los hallazgos de estudios mexicanos y ecuatorianos.
Palabras clave: Leucemia, transcritos de fusión, transcritos b2a2 y b3a2, reacción en cadena de la polimerasa (PCR), fusión BCR/ABL
HIGH PROPORTION OF BCR/ABL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN COLOMBIAABSTRACTMethods: By RT-PCR analysis of mRNA extracted from peripheral blood leukocytes obtained from patients evaluated, 67% (eight) presented the b2a2 and 33% (four) presented the b3a2 transcript. Conclusion: This larger proportion of b2a2 differs from that observed in other global studies: England, Japan, Italy, Spain but is close to the findings of Mexican and Ecuadorian studies.
Key words: Leukemia, fusion transcripts, b2a2 and b3a2 transcripts, polymerase chain reaction (PCR), BCR/ABL fusion
Biografía del autor/a
Iván Hernández Ramírez, Universidad Cooperativa de Colombia, sede Pasto
Jaime Alberto Gavilanes, Universidad Cooperativa de Colombia, sede Pasto
María Edilma Bastidas de Erazo, Hospital infantil los Ángeles-Pasto.
María del Rosario Álvarez Venegas, Hospital Infantil los Ángeles-Pasto.
Patricia Concha, Hospital Infantil los Ángeles-Pasto
Referencias bibliográficas
Dunedin G. The story of chronic myeloid leukaemia. Br J Haematol.2000; 1(10):2-11.
Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature.1973; 243:290-3.
Nowell P, Hungerford D. A minute chromosome in chronic granulocytic leukemia. Science.1960;132:1497.
Quintas-Cardama A, Cortes JA. Chronic Myeloid Leukemia: Diagnosis and treatment. Mayo Clinic Proceedings.2006;81:973-88.
Testoni N, Marzocchi G, Luatti S, Amabile M, et al. Chronic Myeloid Leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMENA CML WP. Blood 2009;114:4939-43.
Goldman J, Melo J. Chronic myeloid leukemia. Advances in biology and new approaches to treatment. N Engl J Med.2003;349:1451-64.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working group 1996 guidelin. Blood.2008;111(12):5446-56.
Rawstron AC, Bennett FL, O´Connor SJ, Marwan K, James AL, Fenton DP et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med.2008;359(6): 575-783.
Faderl S, Talpaz M, Estrov Z, O´Brien S, Kurzrock R, Kantarjian HM. The Biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-72
Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and mRNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol.1995;89:546-54
Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, Tanabe Y, Ohki I, Dan K, Ozawa K, Asano S, Nomura T. A possible correlation between the type of bcr/abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia.Blood.1991;78:3125-7.
Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S. Detection molecular variants of BCR/ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcrptase polymerase chain reaction (RT-PCR). J Med Assoc Thai.2000;83:928-35.
Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit.2002;8:BR193-7.
Seferynska I, Brojer E, Sankowska M, Majewski M, Maj S. A relationship between the breakpoint of the bcr gene and some hematologic parameters in patients with chronic myelogenous leukemia. Acta Haematol Pol.1995;26:385-91.
Martinelli G, Testoni N, Montefusco V, Amabile M, Saglio G, Ottaviani E, et al. Detection of bcr/abl transcript in chronic myelogenous leukemia patients by reversetranscription- polymerase chain reaction and capillary electrophoresis. Haematologica.1998;83:593-601.
Cervantes F, Colomer D, Vives-Corrons JL, RozmanC, Montserrat E. Chronic Myeloid Leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia. 1996;10:1241-43.
Paz-y-Mino C, Burgos R, Morillo SA, Santos JC,Fiallo BF, Leone PE. BCR/ABL rearreangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America. Cancer Genet Cytogenet.2002;132:65-7.
Meza-Espinosa JP, Gutierrez-Angulo M, Vazquez- Cardenas A, Delgado-Lamas JL, Esparza-Flores MA, Gonzalez-Garcia JR. Prevalence of the BCR/ ABL transcripts in Mexican patients with chronic myelogenous leukemia. Rev Investigación Clinica. 2007;59(5):338-341.
Hernández I, Gavilanes JA. Diagnostico de leucemia mediante bcr/abl. Revista Memorias.2011;9(15):9-16.
Giles FJ, O´Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. 2009;23(10):1-10.
Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann R. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia.2009;23: 602–604.
Cross NCP, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval J-L, Goldman JM. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders:some common and contrasting features. Leukemia.2008; 22:1975–1989.
Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner C-M. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood.2009;107(2):742-751.
Van Dongen, JJM., E.A. Macintyre, J.A. Gabert, E. Delabesse, V. Rossi, G. Saglio, E. Gottardi, A. Rambaldi, G. Dotti, F. Griesinger, A. Parreira, P. Gameiro, M. González, M. Malec, A.W. Langerak, J.F. San Miguel & A. Biondi. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia.1999;13:1901–1928.
Rosas-Cabral A, Martinez-Mancilla M, Ayala-Sanchez M, Vela-Ojeda J, Bahena-Resendiz P, Vadillo-Buenfil M, et al. Análisis del tipo de transcrito bcr-abl y su relación con la cuenta plaquetaria en pacientes mexicanos con leucemia mieloide crónica. Gac Méd Méx.2003;139(6):553-59.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidin Thiocyanate-phenolchloroform extraction. Anal Biochem. 1987;162:156-9 -
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Copyright
ANM de Colombia
Los autores deben declarar revisión, validación y aprobación para publicación del manuscrito, además de la cesión de los derechos patrimoniales de publicación, mediante un documento que debe ser enviado antes de la aparición del escrito. Puede solicitar el formato a través del correo revistamedicina@anmdecolombia.org.co o descargarlo directamente Documento Garantías y cesión de derechos.docx
Copyright
ANM de Colombia
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent.
